WHAT IS CLAIMED IS:

1. Use of 0.5% to 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, in the manufacture of a pharmaceutical composition for the treatment of vitiligo in an affected skin area of a patient,

wherein the pharmaceutical composition is to be topically administered to the affected skin area of the patient once per day or twice per day for 52 weeks, and the vitiligo is nonsegmental vitiligo,

wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient, and

wherein the treatment does not comprise phototherapy.

2. The use of claim 1, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.

3. The use of claim 1 or 2, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 1.5% w/w twice per day.

4. The use of claim 1 or 2, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 0.5% w/w once per day.

5. The use of any one of claims 1-4, wherein the affected skin area comprises the lower extremities of the patient.

6. The use of any one of claims 1-5, wherein the affected skin area comprises the trunk of the patient.

7. The use of any one of claims 1-6, wherein the affected skin area comprises the feet of the patient.

8. The use of any one of claims 1-7, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is at least one of the lower extremities, the trunk, and the feet.

9. The use of any one of claims 1-8, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the lower extremities.

10. The use of any one of claims 1-9, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the trunk.

11. The use of any one of claims 1-10, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the feet.

12. The use of claims 8-11, wherein the patient achieves a 25% or greater improvement in Vitiligo Area Scoring Index in the affected skin area that is at least one of the lower extremities, the trunk, and the feet after 52 weeks of the administration.

13. The use of any one of claims 8-12, wherein the patient:

has at least 0.5% facial body surface area affected by vitiligo at baseline and at least 3% non-facial body surface area affected by vitiligo at baseline; and

has been clinically diagnosed with vitiligo.

14. The use of claim 13, wherein the patient is aged 12 years or older.

15. The use of any one of claims 1-14, wherein the pharmaceutical composition is an oil-in-water emulsion, which is a cream.

16. Use of 0.5% to 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, in the manufacture of a pharmaceutical composition for the treatment of vitiligo in an affected skin area of a patient,

wherein the pharmaceutical composition is to be topically administered to the affected skin area of the patient once per day or twice per day for 52 weeks, and the vitiligo is nonsegmental vitiligo,

wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient,

wherein the treatment does not comprise phototherapy, and

wherein the pharmaceutical composition is to be topically administered and is to be continued to achieve a 50% or greater improvement in Vitiligo Area Scoring Index in the affected skin area that is at least one of the lower extremities, the trunk, and the feet after 52 weeks.

17. The use of claim 16, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 1.5% w/w twice per day.

18 The use of claim 16, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 0.5% w/w once per day.

19. The use of any one of claims 16-18, wherein the patient:

has at least 0.5% facial body surface area affected by vitiligo at baseline and at least 3% non-facial body surface area affected by vitiligo at baseline; and

has been clinically diagnosed with vitiligo.

20. The use of any one of claims 16-19, wherein the patient is aged 12 years or older.

21. The use of any one of claims 16-20, wherein the pharmaceutical composition is an oil-in-water emulsion, which is a cream.

22. The use of any one of claims 16-21, wherein the affected skin area is the lower extremities.

23. The use of any one of claims 16-22, wherein the affected skin area is the trunk.

24. The use of any one of claims 16-23, wherein the affected skin area is the feet.